Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
5-day change
1st Jan Change
17.88
USD
+1.53%
+5.74%
+1.94%
Presentation Operator MessageOperator (Operator)Good day, and thank you for standing by. Welco...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises
Apr. 23
MT
Transcript : Kiniksa Pharmaceuticals, Ltd., Q1 2024 Earnings Call, Apr 23, 2024
Apr. 23
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Posts Q1 Revenue $79.9M, vs. Street Est of $78.5M
Apr. 23
MT
Kiniksa Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 23
CI
Wedbush Adjusts Kiniksa Pharmaceuticals' PT to $30 From $28, Maintains Outperform Rating
Apr. 03
MT
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
Apr. 02
CI
Kiniksa Pharmaceuticals' Q4 Earnings, Revenue Increase
Feb. 28
MT
Transcript : Kiniksa Pharmaceuticals, Ltd., Q4 2023 Earnings Call, Feb 28, 2024
Feb. 28
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Reports Q4 Revenue $83.4M, vs. Street Est of $72.3M
Feb. 28
MT
Kiniksa Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Feb. 28
CI
Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for the Year 2024
Jan. 08
CI
Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 01:30 PM
Jan. 08
Wedbush Lifts Kiniksa Pharmaceuticals' PT to $25 From $23 Ahead of Planned Q1 Reporting of Initial Data on KPL-404; Maintains Outperform Rating
Jan. 02
MT
Transcript : Kiniksa Pharmaceuticals, Ltd., Q3 2023 Earnings Call, Oct 31, 2023
23-10-31
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Reports Q3 Revenue $67M, vs. Street Est of $64.4M
23-10-31
MT
Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for 2023
23-10-31
CI
Kiniksa Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
23-10-31
CI
Insider Sell: Kiniksa Pharmaceuticals
23-07-27
MT
Sector Update: Health Care Stocks Steady in Late Afternoon Trading
23-07-25
MT
Sector Update: Health Care
23-07-25
MT
Kiniksa Pharmaceuticals' Shares Rise as Q2 Net Income, Revenue Advance
23-07-25
MT
Top Midday Gainers
23-07-25
MT
Wedbush Adjusts Kiniksa Pharmaceuticals Price Target to $23 From $21, Maintains Outperform Rating
23-07-25
MT
- (KNSA) KINIKSA PHARMACEUTICALS Q2 EPS $0.21
23-07-25
MT
Transcript : Kiniksa Pharmaceuticals, Ltd., Q2 2023 Earnings Call, Jul 25, 2023
23-07-25
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Companyâs ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Companyâs Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
More about the company
Last Close Price
17.88
USD
Average target price
29.2
USD
Spread / Average Target
+63.31%
Consensus
1st Jan change
Capi.
+1.94% 1.27B -2.31% 103B +0.56% 95.28B +1.69% 22.15B -17.37% 21.02B -9.30% 18.15B -41.01% 16.73B -14.85% 16.05B +3.21% 13.68B +33.54% 12.17B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1